{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=33",
    "query": {
      "intervention": "Combination Agent",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 5568,
    "total_pages": 557,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T14:16:40.829Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04208958",
      "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Melanoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "VE800",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Vedanta Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2020-01-23",
      "completion_date": "2023-02-23",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04208958"
    },
    {
      "nct_id": "NCT03469310",
      "title": "Minimizing Narcotic Analgesics After Endocrine Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Thyroid Nodule",
        "Thyroid Neoplasms",
        "Thyroid Goitre",
        "Thyroid Diseases",
        "Parathyroid Diseases",
        "Parathyroid Adenoma",
        "Parathyroid Hyperplasia"
      ],
      "interventions": [
        {
          "name": "Acetaminophen 500Mg Cap",
          "type": "DRUG"
        },
        {
          "name": "Tylenol #3 Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Tramadol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Minerva A Romero Arenas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2018-03-09",
      "completion_date": "2020-10-02",
      "has_results": false,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 1,
      "location_summary": "Edinburg, Texas",
      "locations": [
        {
          "city": "Edinburg",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03469310"
    },
    {
      "nct_id": "NCT01110876",
      "title": "Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain Cancer",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-06",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110876"
    },
    {
      "nct_id": "NCT00000989",
      "title": "The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytomegalovirus Retinitis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "DRUG"
        },
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "13 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": null,
      "completion_date": "1992-07",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000989"
    },
    {
      "nct_id": "NCT05877430",
      "title": "Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NSCLC",
        "HNSCC",
        "Melanoma",
        "Metastatic Cancer",
        "Advanced Solid Tumor",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "CJRB-101",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CJ Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2023-09-11",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877430"
    },
    {
      "nct_id": "NCT00300430",
      "title": "Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemia",
        "Coronary Heart Disease",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "ABT-335 and rosuvastatin calcium",
          "type": "DRUG"
        },
        {
          "name": "ABT-335 and atorvastatin calcium",
          "type": "DRUG"
        },
        {
          "name": "ABT-335 and simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1911,
      "start_date": "2006-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2009-07-23",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 1,
      "location_summary": "North Chicago, Illinois",
      "locations": [
        {
          "city": "North Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00300430"
    },
    {
      "nct_id": "NCT04256317",
      "title": "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome/Neoplasm",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "ASTX030 (cedazuridine + azacitidine)",
          "type": "DRUG"
        },
        {
          "name": "Cedazuridine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 316,
      "start_date": "2020-05-21",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Orange, California • New Haven, Connecticut + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04256317"
    },
    {
      "nct_id": "NCT01806324",
      "title": "A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertension",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "HL040XC",
          "type": "DRUG"
        },
        {
          "name": "Losartan + Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HanAll BioPharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "19 Years to 50 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2012-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-07",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01806324"
    },
    {
      "nct_id": "NCT00002524",
      "title": "Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bleomycin Sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride (DOX)",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Pentamidine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Trimethoprim-Sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine (AZT)",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "1993-06",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002524"
    },
    {
      "nct_id": "NCT04188262",
      "title": "Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peripheral Arterial Disease",
        "Peripheral Vascular Diseases",
        "Catheterization, Peripheral"
      ],
      "interventions": [
        {
          "name": "NVS Therapy",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Alucent Biomedical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-05-22",
      "completion_date": "2022-05-31",
      "has_results": false,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-11-15T14:16:40.829Z",
      "location_count": 4,
      "location_summary": "Houma, Louisiana • Saginaw, Michigan • Raleigh, North Carolina + 1 more",
      "locations": [
        {
          "city": "Houma",
          "state": "Louisiana"
        },
        {
          "city": "Saginaw",
          "state": "Michigan"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Kingsport",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04188262"
    }
  ]
}